Johnson & Johnson EPS History: Annual & Quarterly (JNJ)
Johnson & Johnson's diluted EPS was $11.03 for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-28 | $11.03 | $11.13 | $5.24 | +90.50% |
| 2024 | 2024-12-29 | $5.79 | $5.84 | -$7.93 | −57.80% |
| 2023 | 2023-12-31 | $13.72 | $13.88 | $6.99 | +103.86% |
| 2022 | 2023-01-01 | $6.73 | $6.83 | -$1.08 | −13.83% |
| 2021 | 2022-01-02 | $7.81 | $7.93 | $2.30 | +41.74% |
| 2020 | 2021-01-04 | $5.51 | $5.59 | -$0.12 | −2.13% |
| 2019 | 2019-12-29 | $5.63 | $5.72 | $0.02 | +0.36% |
| 2018 | 2018-12-30 | $5.61 | $5.70 | $5.14 | +1093.62% |
| 2017 | 2017-12-31 | $0.47 | $0.48 | -$5.46 | −92.07% |
| 2016 | 2017-01-01 | $5.93 | $6.04 | $0.45 | +8.21% |
| 2015 | 2016-01-03 | $5.48 | $5.56 | -$0.22 | −3.86% |
| 2014 | 2014-12-28 | $5.70 | $5.80 | $0.89 | +18.50% |
| 2013 | 2013-12-29 | $4.81 | $4.92 | $0.95 | +24.61% |
| 2012 | 2012-12-30 | $3.86 | $3.94 | $0.37 | +10.60% |
| 2011 | 2012-01-01 | $3.49 | $3.54 | -$1.29 | −26.99% |
| 2010 | 2011-01-02 | $4.78 | $4.85 | $0.38 | +8.64% |
| 2009 | 2010-01-03 | $4.40 | $4.45 | -$0.17 | −3.72% |
| 2008 | 2008-12-28 | $4.57 | $4.62 | $0.94 | +25.90% |
| 2007 | 2007-12-30 | $3.63 | $3.67 | — | — |
Johnson & Johnson quarterly diluted eps
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | $2.27 | $2.30 | -$0.02 | −0.87% |
| Q1 2026 | 2026-03-29 | $2.14 | $2.17 | -$2.40 | −52.86% |
| Q4 2025 | 2025-12-28 | $2.10 | $2.12 | — | — |
| Q3 2025 | 2025-09-28 | $2.12 | $2.14 | $1.01 | +90.99% |
| Q2 2025 | 2025-06-29 | $2.29 | $2.30 | $0.36 | +18.65% |
| Q1 2025 | 2025-03-30 | $4.54 | $4.57 | $3.20 | +238.81% |
| Q3 2024 | 2024-09-29 | $1.11 | $1.12 | -$9.10 | −89.13% |
| Q2 2024 | 2024-06-30 | $1.93 | $1.95 | -$0.03 | −1.53% |
| Q1 2024 | 2024-03-31 | $1.34 | $1.35 | $1.37 | — |
| Q4 2023 | 2023-12-31 | $1.67 | $1.68 | $0.34 | +25.56% |
| Q3 2023 | 2023-10-01 | $10.21 | $10.32 | $8.53 | +507.74% |
| Q2 2023 | 2023-07-02 | $1.96 | $1.98 | $0.16 | +8.89% |
| Q1 2023 | 2023-04-02 | -$0.03 | -$0.03 | -$1.96 | — |
| Q4 2022 | 2023-01-01 | $1.33 | $1.35 | — | — |
| Q3 2022 | 2022-10-02 | $1.68 | $1.70 | $0.31 | +22.63% |
| Q2 2022 | 2022-07-03 | $1.80 | $1.83 | -$0.55 | −23.40% |
| Q1 2022 | 2022-04-03 | $1.93 | $1.96 | -$0.39 | −16.81% |
| Q3 2021 | 2021-10-03 | $1.37 | $1.39 | $0.04 | +3.01% |
| Q2 2021 | 2021-07-04 | $2.35 | $2.38 | $0.99 | +72.79% |
| Q1 2021 | 2021-04-04 | $2.32 | $2.35 | $0.15 | +6.91% |
| Q3 2020 | 2020-09-27 | $1.33 | $1.35 | $0.67 | +101.52% |
| Q2 2020 | 2020-06-28 | $1.36 | $1.38 | -$0.72 | −34.62% |
| Q1 2020 | 2020-03-29 | $2.17 | $2.20 | $0.78 | +56.12% |
| Q4 2019 | 2019-12-29 | $1.50 | $1.52 | $0.38 | +33.93% |
| Q3 2019 | 2019-09-29 | $0.66 | $0.67 | -$0.78 | −54.17% |
| Q2 2019 | 2019-06-30 | $2.08 | $2.11 | $0.63 | +43.45% |
| Q1 2019 | 2019-03-31 | $1.39 | $1.41 | -$0.21 | −13.13% |
| Q4 2018 | 2018-12-30 | $1.12 | $1.14 | $5.11 | — |
| Q3 2018 | 2018-09-30 | $1.44 | $1.47 | $0.07 | +5.11% |
| Q2 2018 | 2018-07-01 | $1.45 | $1.47 | $0.05 | +3.57% |
| Q1 2018 | 2018-04-01 | $1.60 | $1.63 | -$0.01 | −0.62% |
| Q4 2017 | 2017-12-31 | -$3.99 | -$3.99 | -$5.37 | — |
| Q3 2017 | 2017-10-01 | $1.37 | $1.40 | -$0.16 | −10.46% |
| Q2 2017 | 2017-07-02 | $1.40 | $1.42 | -$0.03 | −2.10% |
| Q1 2017 | 2017-04-02 | $1.61 | $1.63 | $0.02 | +1.26% |
| Q4 2016 | 2017-01-01 | $1.38 | $1.41 | $0.23 | +20.00% |
| Q3 2016 | 2016-10-02 | $1.53 | $1.56 | $0.33 | +27.50% |
| Q2 2016 | 2016-07-03 | $1.43 | $1.46 | -$0.18 | −11.18% |
| Q1 2016 | 2016-04-03 | $1.59 | $1.62 | $0.06 | +3.92% |
| Q4 2015 | 2016-01-03 | $1.15 | $1.16 | $0.26 | +29.21% |
| Q3 2015 | 2015-09-27 | $1.20 | $1.21 | -$0.46 | −27.71% |
| Q2 2015 | 2015-06-28 | $1.61 | $1.63 | $0.10 | +6.62% |
| Q1 2015 | 2015-03-29 | $1.53 | $1.55 | -$0.11 | −6.71% |
| Q4 2014 | 2014-12-28 | $0.89 | $0.90 | -$0.34 | −27.64% |
| Q3 2014 | 2014-09-28 | $1.66 | $1.69 | $0.62 | +59.62% |
| Q2 2014 | 2014-06-29 | $1.51 | $1.53 | $0.18 | +13.53% |
| Q1 2014 | 2014-03-30 | $1.64 | $1.67 | $0.42 | +34.43% |
| Q4 2013 | 2013-12-29 | $1.23 | $1.25 | $0.32 | +35.16% |
| Q3 2013 | 2013-09-29 | $1.04 | $1.06 | -$0.01 | −0.95% |
| Q2 2013 | 2013-06-30 | $1.33 | $1.36 | $0.83 | +166.00% |
| Q1 2013 | 2013-03-31 | $1.22 | $1.25 | -$0.19 | −13.48% |
| Q4 2012 | 2012-12-30 | $0.91 | $0.93 | $0.83 | +1037.50% |
| Q3 2012 | 2012-09-30 | $1.05 | $1.08 | -$0.10 | −8.70% |
| Q2 2012 | 2012-07-01 | $0.50 | $0.51 | -$0.50 | −50.00% |
| Q1 2012 | 2012-04-01 | $1.41 | $1.43 | $0.16 | +12.80% |
| Q4 2011 | 2012-01-01 | $0.08 | $0.08 | -$0.62 | −88.57% |
| Q3 2011 | 2011-10-02 | $1.15 | $1.17 | -$0.08 | −6.50% |
| Q2 2011 | 2011-07-03 | $1.00 | $1.01 | -$0.23 | −18.70% |
| Q1 2011 | 2011-04-03 | $1.25 | $1.27 | -$0.37 | −22.84% |
| Q4 2010 | 2011-01-02 | $0.70 | $0.71 | -$0.09 | −11.39% |
| Q3 2010 | 2010-10-03 | $1.23 | $1.24 | $0.03 | +2.50% |
| Q2 2010 | 2010-07-04 | $1.23 | $1.25 | $0.08 | +6.96% |
| Q1 2010 | 2010-04-04 | $1.62 | $1.64 | $0.36 | +28.57% |
| Q4 2009 | 2010-01-03 | $0.79 | $0.80 | — | — |
| Q3 2009 | 2009-09-27 | $1.20 | $1.21 | $0.03 | +2.56% |
| Q2 2009 | 2009-06-28 | $1.15 | $1.16 | -$0.02 | −1.71% |
| Q1 2009 | 2009-03-29 | $1.26 | $1.27 | — | — |
| Q3 2008 | 2008-09-28 | $1.17 | $1.19 | — | — |
| Q2 2008 | 2008-06-29 | $1.17 | $1.18 | — | — |
Johnson & Johnson diluted eps trends
Over the last five fiscal years, Johnson & Johnson's diluted eps increased from $5.51 to $11.03, a change of $5.52. The latest reported quarter, Q2 2026, shows $2.27.
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...